YIL 781 is a selective ghrelin receptor (GHSR1a) antagonist with a Ki value of 17 nM[1]. YIL 781 inhibits ghrelin-induced calcium response and improves glucose homeostasis in rats[2]. Oral administration of YIL 781 to insulin-resistant diet-induced obesity (DIO) rats reduces blood glucose fluctuations[3].
In vitro, pretreatment of GHSR1a-expressing HEK-293T cells with YIL 781 (1µM) for 10min completely reversed ghrelin-mediated forskolin-induced decrease in cAMP levels (approximately 25%)[4]. Pretreatment of primary cultures of striatal neurons with YIL 781 (2µM) antagonized the GHSR1a signaling pathway induced by auxin-releasing peptide[5].
In vivo, intraperitoneal injection of YIL 781 (5mg/kg/day) in mice for 1 week significantly inhibited prostate enlargement induced by a high-fat diet and testosterone propionate (TP)[6]. YIL 781 (3mg/kg) reversed the effect of ulimorelin on renal sympathetic nerve activity (RSNA) in rats by intravenous injection[7].
References:
[1] Esler W P, Rudolph J, Claus T H, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss[J]. Endocrinology, 2007, 148(11): 5175-5185.
[2] Perdonà E, Faggioni F, Buson A, et al. Pharmacological characterization of the ghrelin receptor antagonist, GSK1614343 in rat RC-4B/C cells natively expressing GHS type 1a receptors[J]. European journal of pharmacology, 2011, 650(1): 178-183.
[3] Sangiao-Alvarellos S, Cordido F. Effect of ghrelin on glucose‐insulin homeostasis: therapeutic implications[J]. International Journal of Peptides, 2010, 2010(1): 234709.
[4] Lillo J, Lillo A, Zafra D A, et al. Identification of the ghrelin and cannabinoid CB2 receptor heteromer functionality and marked upregulation in striatal neurons from offspring of mice under a high-fat diet[J]. International journal of molecular sciences, 2021, 22(16): 8928.
[5] Aguinaga D, Medrano M, Cordomí A, et al. Cocaine blocks effects of hunger hormone, ghrelin, via interaction with neuronal sigma-1 receptors[J]. Molecular neurobiology, 2019, 56(2): 1196-1210.
[6] Gu M, Liu C, Yang T Y, et al. High-fat diet induced gut microbiota alterations associating with Ghrelin/Jak2/Stat3 up-regulation to promote benign prostatic hyperplasia development[J]. Frontiers in cell and developmental biology, 2021, 9: 615928.
[7] Callaghan B, Kosari S, Pustovit R V, et al. Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor[J]. British Journal of Pharmacology, 2014, 171(5): 1275-1286.
YIL 781是一种选择性的胃饥饿素受体(GHSR1a)拮抗剂,Ki值为17nM[1]。YIL 781能够抑制饥饿素诱导的钙反应,改善大鼠体内葡萄糖稳态[2]。口服YIL 781治疗胰岛素抵抗饮食诱导性肥胖(DIO)大鼠能够减少血糖波动[3]。
在体外,YIL 781(1µM)预处理表达GHSR1a的HEK-293T细胞10min,能够完全逆转由ghrelin介导的Forskolin诱导的cAMP水平降低(约25%)[4]。YIL 781(2µM)预处理纹状体神经元原代培养物,拮抗了生长素释放肽诱导的GHSR1a信号通路[5]。
在体内,YIL 781(5mg/kg/day)通过腹腔注射处理小鼠1周,显著抑制了高脂饮食和丙酸睾酮(TP)引起的前列腺增大[6]。YIL 781(3mg/kg)通过静脉注射处理大鼠,逆转了ulimorelin对大鼠肾交感神经活动(RSNA)的影响[7]。
















